Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study

Keywords

Secondary progressive multiple sclerosis

Active disease

Siponimod

S1P modulator

Age subgroups

Adverse events

Abbreviations3mCDP

3-month confirmed disability progression

6mCDP

6-month confirmed disability progression

CDP

Confirmed disability progression

DMT

Disease-modifying therapy

EDSS

Expanded Disability Status Scale

RRMS

Relapsing-remitting multiple sclerosis

S1P

Sphingosine 1-phosphate

SPMS

Secondary progressive multiple sclerosis

© 2023 The Authors. Published by Elsevier B.V.

留言 (0)

沒有登入
gif